Related Experiment Videos
[Medical treatment of primary biliary cirrhosis]
1Service d'Hépato-gastroentérologie, Centre Hospitalier de l'Université de Liège.
Insights
Current primary biliary cirrhosis treatments focus on complications. While cyclosporine and ursodeoxycholic acid show promise for liver biochemistry, long-term studies are needed to confirm their effectiveness in halting disease progression and improving survival.
Area of Science:
- Hepatology
- Gastroenterology
Context:
- Primary biliary cirrhosis (PBC) is a chronic liver disease.
- Treatment strategies for PBC are multifaceted.
Purpose:
- To review current medical treatments for primary biliary cirrhosis.
- To evaluate the efficacy of emerging therapies for PBC.
Summary:
- Medical management of PBC involves treating complications like cholestasis and portal hypertension.
- No current drug definitively halts PBC progression or improves survival.
- Cyclosporine and ursodeoxycholic acid demonstrate potential in improving liver biochemistry, but require further long-term validation.
Impact:
- Highlights the need for disease-modifying therapies for primary biliary cirrhosis.
- Underscores the importance of ongoing clinical trials for PBC treatment evaluation.
Abstract:
The medical treatment of primary biliary cirrhosis can be divided into two parts: the treatment of the complications (cholestasis and portal hypertension) and the treatment of the underlying disease. As regards the treatment of the disease itself, there is to date no drug which has been shown to ameliorate the pathological process and to prolong survival: cyclosporine and ursodeoxycholic acid, recently used have shown promising responses in liver biochemistry but long-term controlled studies are required to assess their effectiveness on the disease process and on survival.